Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6 Billion
Key Points Johnson & Johnson will acquire Intra-Cellular Therapies for $14.6 billion. The deal values Intra-Cellular shares at $132 each, a 39% premium. Intra-Cellular’s Caplyta drug generated $175 million in Q3 2024 sales. Analysts expect Caplyta’s sales to top $2.5...